Treace Medical Concepts (TMCI) CEO details 13,219-share Form 4 update

Rhea-AI Filing Summary

Treace Medical Concepts, Inc. reported an insider ownership update for Chief Executive Officer and director John T. Treace. On January 10, 2026, a Form 4 lists a transaction in which 13,219 shares of common stock were disposed of at a price of $0.00 per share under transaction code F, leaving 6,775,887 common shares directly beneficially owned. This direct position includes 363,867 restricted stock units.

The filing also reports additional indirect holdings of common stock attributed to Mr. Treace’s spouse and various trusts, with share amounts of 1,605,000, 1,471,250, 1,839,063, and 408,816. The reporting person disclaims beneficial ownership of shares held by his wife directly or in trusts she controls, as well as shares held in trusts for which he serves as trustee or co‑trustee.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Treace John T.

(Last) (First) (Middle)

C/O TREACE MEDICAL CONCEPTS, INC.

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA FL 32081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/10/2026		F		13,219	D	$0	6,775,887(1)	D
Common Stock								1,605,000(2)	I	By spouse
Common Stock								1,471,250(2)	I	by spouse as trustee of a trust
Common Stock								1,839,063(3)	I	As trustee of a trust
Common Stock								408,816(3)	I	As co-trustee of a trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 363,867 restricted stock units.

2. The Reporting Person disclaims beneficial ownershup of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.

3. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.

	/s/ Lisa Taylor as Attorney-in-fact for John Treace	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TMCI report for John T. Treace?

The Form 4 reports that John T. Treace had 13,219 shares of Treace Medical Concepts common stock disposed of on January 10, 2026 under transaction code F at a price of $0.00 per share, leaving 6,775,887 shares directly beneficially owned.

How many Treace Medical Concepts (TMCI) shares does John T. Treace directly own after the transaction?

After the reported transaction, John T. Treace is shown as directly beneficially owning 6,775,887 shares of TMCI common stock, which the filing notes includes 363,867 restricted stock units.

What indirect holdings of TMCI stock related to John T. Treace are disclosed?

The Form 4 discloses indirect holdings of TMCI common stock totaling 1,605,000 shares held by his spouse, 1,471,250 shares held by his spouse as trustee of a trust, 1,839,063 shares held in a trust where he is trustee, and 408,816 shares held in a trust where he is co‑trustee.

Does John T. Treace claim beneficial ownership of his spouse’s and trust-held TMCI shares?

No. The footnotes state that the reporting person disclaims beneficial ownership of shares held by his wife directly or in trusts where she is trustee or co‑trustee, and also disclaims beneficial ownership of shares held in trusts for which he serves as trustee or co‑trustee.

What does transaction code F mean in this TMCI Form 4?

The Form 4 lists the common stock transaction under transaction code F. While the filing identifies the code, it does not provide a narrative description of the code’s meaning within the text provided.

What positions does John T. Treace hold at Treace Medical Concepts (TMCI)?

John T. Treace is identified in the Form 4 as a director, Chief Executive Officer, and a 10% owner of Treace Medical Concepts, Inc.